Doub James B, Chan Benjamin, Johnson Aaron J
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
The Doub Laboratory of Translational Bacterial Research, University of Maryland School of Medicine, Baltimore, MD, USA.
IDCases. 2023 Jul 21;33:e01854. doi: 10.1016/j.idcr.2023.e01854. eCollection 2023.
Chronic prosthetic joint infections are difficult to treat without conducting revision surgery because conventional antibiotics cannot eradicate bacteria that reside in biofilms. Consequently, novel therapeutics are needed to help treat prosthetic joint infections with one being bacteriophage therapy given its innate biofilm activity. Herein a sixty-nine-year-old man with a recalcitrant prosthetic joint infection is discussed. The patient was successfully treated with personalized bacteriophage therapy and after two years of follow up he has not had a clinical recurrence. Overall, this case report supports that bacteriophage therapy for prosthetic joint infections has promise to reduce the morbidity that is associated with current treatments. However, more research is needed to assess whether this therapeutic is helping eradicate infections or if it is making bacteria less pathogenic. This is an important point which will need to be evaluated as this therapeutic continues to be developed for all infections.
慢性人工关节感染若不进行翻修手术则难以治疗，因为传统抗生素无法根除生物膜中的细菌。因此，需要新的治疗方法来帮助治疗人工关节感染，其中一种是噬菌体疗法，因其具有固有的生物膜活性。本文讨论了一名患有顽固性人工关节感染的69岁男性。该患者通过个性化噬菌体疗法成功治愈，经过两年的随访，他没有出现临床复发。总体而言，本病例报告支持噬菌体疗法治疗人工关节感染有望降低与当前治疗相关的发病率。然而，需要更多的研究来评估这种疗法是否有助于根除感染，或者它是否会使细菌致病性降低。这是一个重要的问题，随着这种疗法继续针对所有感染进行开发，将需要对此进行评估。
